Cancer Cell

, volume 19 , issue 1 , pages 101-113

An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells

Nicholas C. Wilson ¹

Becky Yang ¹

Annie Yang ¹

Stefanie Loeser ²

Scot Marsters ¹

David M. Lawrence ¹

Yun Li ¹

Robert Pitti ¹

KLARA TOTPAL ³

Sharon Yee ³

Sarajane Ross ³

Jean-Michel Vernes ⁴

Yanmei Lu ⁴

Cam Adams ⁵

Rienk Offringa ²

Bob Kelley ⁵

Sarah G. Hymowitz ⁶

Dylan Daniel ¹

Gloria Meng ⁴

Avi Ashkenazi ¹

Hide authors affiliations Show authors affiliations: 6 affiliations

Department of Molecular Oncology, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA. |

Department of Discovery Immunology, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA |

Department of Cancer Signaling and Translational Oncology, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA |

⁴

Department of Assay & Automation Technology, Genentech, Inc. 1 DNA Way, South San Francisco, CA 94080, USA |

⁵

Department of Antibody Engineering, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA. |

⁶

Department of Structural Biology, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA |

Publication type: Journal Article

Publication date: 2011-01-20

Elsevier

Cancer Cell

scimago Q1

wos Q1

SJR: 19.027

CiteScore: 57.7

Impact factor: 44.5

ISSN: 15356108, 18783686

DOI: 10.1016/j.ccr.2010.11.012

Copy DOI

PubMed ID: 21251615

Cancer Research

Oncology

Cell Biology

Abstract

Antibodies to cell-surface antigens trigger activatory Fcγ receptor (FcγR)-mediated retrograde signals in leukocytes to control immune effector functions. Here, we uncover an FcγR mechanism that drives antibody-dependent forward signaling in target cells. Agonistic antibodies to death receptor 5 (DR5) induce cancer-cell apoptosis and are in clinical trials; however, their mechanism of action in vivo is not fully defined. Interaction of the DR5-agonistic antibody drozitumab with leukocyte FcγRs promoted DR5-mediated tumor-cell apoptosis. Whereas the anti-CD20 antibody rituximab required activatory FcγRs for tumoricidal function, drozitumab was effective in the context of either activatory or inhibitory FcγRs. A CD40-agonistic antibody required similar FcγR interactions to stimulate nuclear factor-κB activity in B cells. Thus, FcγRs can drive antibody-mediated receptor signaling in target cells.

Found

1 citation

Yagolovich Anne

🥼 🤝

PhD in Biological/biomedical sciences, lecturer

31 publications, 279 citations, 4 reviews

h-index: 10

Lomonosov Moscow State University

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences

Research interests

Apoptosis

1 citation

Nagata Satoshi

50 publications, 1 746 citations, 2 reviews

h-index: 26

National Institute of Biomedical Innovation, Health and Nutrition

Top-30

Journals

	2 4 6 8 10
Cancer Cell	Cancer Cell, 10, 4.33% Cancer Cell 10 publications, 4.33%
Nature Reviews Drug Discovery	Nature Reviews Drug Discovery, 7, 3.03% Nature Reviews Drug Discovery 7 publications, 3.03%
mAbs	mAbs, 7, 3.03% mAbs 7 publications, 3.03%
Molecular Cancer Therapeutics	Molecular Cancer Therapeutics, 7, 3.03% Molecular Cancer Therapeutics 7 publications, 3.03%
Cancers	Cancers, 6, 2.6% Cancers 6 publications, 2.6%
Cell Death and Differentiation	Cell Death and Differentiation, 6, 2.6% Cell Death and Differentiation 6 publications, 2.6%
Cell Death and Disease	Cell Death and Disease, 6, 2.6% Cell Death and Disease 6 publications, 2.6%
Journal of Immunology	Journal of Immunology, 5, 2.16% Journal of Immunology 5 publications, 2.16%
Clinical Cancer Research	Clinical Cancer Research, 5, 2.16% Clinical Cancer Research 5 publications, 2.16%
Journal of Biological Chemistry	Journal of Biological Chemistry, 4, 1.73% Journal of Biological Chemistry 4 publications, 1.73%
OncoImmunology	OncoImmunology, 4, 1.73% OncoImmunology 4 publications, 1.73%
Journal of Experimental Medicine	Journal of Experimental Medicine, 4, 1.73% Journal of Experimental Medicine 4 publications, 1.73%
Journal of Clinical Investigation	Journal of Clinical Investigation, 3, 1.3% Journal of Clinical Investigation 3 publications, 1.3%
Science	Science, 3, 1.3% Science 3 publications, 1.3%
Cancer immunology research	Cancer immunology research, 3, 1.3% Cancer immunology research 3 publications, 1.3%
Proceedings of the National Academy of Sciences of the United States of America	Proceedings of the National Academy of Sciences of the United States of America, 3, 1.3% Proceedings of the National Academy of Sciences of the United States of America 3 publications, 1.3%
Expert Opinion on Therapeutic Targets	Expert Opinion on Therapeutic Targets, 2, 0.87% Expert Opinion on Therapeutic Targets 2 publications, 0.87%
Nature Cancer	Nature Cancer, 2, 0.87% Nature Cancer 2 publications, 0.87%
Oncotarget	Oncotarget, 2, 0.87% Oncotarget 2 publications, 0.87%
Antibodies	Antibodies, 2, 0.87% Antibodies 2 publications, 0.87%
International Journal of Molecular Sciences	International Journal of Molecular Sciences, 2, 0.87% International Journal of Molecular Sciences 2 publications, 0.87%
Frontiers in Immunology	Frontiers in Immunology, 2, 0.87% Frontiers in Immunology 2 publications, 0.87%
Cellular and Molecular Immunology	Cellular and Molecular Immunology, 2, 0.87% Cellular and Molecular Immunology 2 publications, 0.87%
Current Oncology Reports	Current Oncology Reports, 2, 0.87% Current Oncology Reports 2 publications, 0.87%
Cancer Immunology, Immunotherapy	Cancer Immunology, Immunotherapy, 2, 0.87% Cancer Immunology, Immunotherapy 2 publications, 0.87%
Scientific Reports	Scientific Reports, 2, 0.87% Scientific Reports 2 publications, 0.87%
Nature Immunology	Nature Immunology, 2, 0.87% Nature Immunology 2 publications, 0.87%
Nature Reviews Clinical Oncology	Nature Reviews Clinical Oncology, 2, 0.87% Nature Reviews Clinical Oncology 2 publications, 0.87%
Nature Communications	Nature Communications, 2, 0.87% Nature Communications 2 publications, 0.87%
	2 4 6 8 10

Publishers

	10 20 30 40 50 60
Springer Nature	Springer Nature, 57, 24.68% Springer Nature 57 publications, 24.68%
Elsevier	Elsevier, 47, 20.35% Elsevier 47 publications, 20.35%
Taylor & Francis	Taylor & Francis, 20, 8.66% Taylor & Francis 20 publications, 8.66%
American Association for Cancer Research (AACR)	American Association for Cancer Research (AACR), 16, 6.93% American Association for Cancer Research (AACR) 16 publications, 6.93%
Wiley	Wiley, 13, 5.63% Wiley 13 publications, 5.63%
MDPI	MDPI, 12, 5.19% MDPI 12 publications, 5.19%
The American Association of Immunologists	The American Association of Immunologists, 5, 2.16% The American Association of Immunologists 5 publications, 2.16%
Frontiers Media S.A.	Frontiers Media S.A., 5, 2.16% Frontiers Media S.A. 5 publications, 2.16%
American Association for the Advancement of Science (AAAS)	American Association for the Advancement of Science (AAAS), 5, 2.16% American Association for the Advancement of Science (AAAS) 5 publications, 2.16%
American Society for Clinical Investigation	American Society for Clinical Investigation, 4, 1.73% American Society for Clinical Investigation 4 publications, 1.73%
American Society for Biochemistry and Molecular Biology	American Society for Biochemistry and Molecular Biology, 4, 1.73% American Society for Biochemistry and Molecular Biology 4 publications, 1.73%
Rockefeller University Press	Rockefeller University Press, 4, 1.73% Rockefeller University Press 4 publications, 1.73%
BMJ	BMJ, 3, 1.3% BMJ 3 publications, 1.3%
Proceedings of the National Academy of Sciences (PNAS)	Proceedings of the National Academy of Sciences (PNAS), 3, 1.3% Proceedings of the National Academy of Sciences (PNAS) 3 publications, 1.3%
American Society of Hematology	American Society of Hematology, 3, 1.3% American Society of Hematology 3 publications, 1.3%
American Chemical Society (ACS)	American Chemical Society (ACS), 3, 1.3% American Chemical Society (ACS) 3 publications, 1.3%
Impact Journals	Impact Journals, 2, 0.87% Impact Journals 2 publications, 0.87%
Ovid Technologies (Wolters Kluwer Health)	Ovid Technologies (Wolters Kluwer Health), 2, 0.87% Ovid Technologies (Wolters Kluwer Health) 2 publications, 0.87%
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii	Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii, 2, 0.87% Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii 2 publications, 0.87%
Oxford University Press	Oxford University Press, 2, 0.87% Oxford University Press 2 publications, 0.87%
Hindawi Limited	Hindawi Limited, 2, 0.87% Hindawi Limited 2 publications, 0.87%
Cold Spring Harbor Laboratory	Cold Spring Harbor Laboratory, 2, 0.87% Cold Spring Harbor Laboratory 2 publications, 0.87%
American Society for Pharmacology and Experimental Therapeutics	American Society for Pharmacology and Experimental Therapeutics, 1, 0.43% American Society for Pharmacology and Experimental Therapeutics 1 publication, 0.43%
Editions E D K	Editions E D K, 1, 0.43% Editions E D K 1 publication, 0.43%
IOS Press	IOS Press, 1, 0.43% IOS Press 1 publication, 0.43%
S. Karger AG	S. Karger AG, 1, 0.43% S. Karger AG 1 publication, 0.43%
Portland Press	Portland Press, 1, 0.43% Portland Press 1 publication, 0.43%
Pharmaceutical Society of Japan	Pharmaceutical Society of Japan, 1, 0.43% Pharmaceutical Society of Japan 1 publication, 0.43%
Public Library of Science (PLoS)	Public Library of Science (PLoS), 1, 0.43% Public Library of Science (PLoS) 1 publication, 0.43%
European Molecular Biology Organization	European Molecular Biology Organization, 1, 0.43% European Molecular Biology Organization 1 publication, 0.43%
	10 20 30 40 50 60

We do not take into account publications without a DOI.
Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.

Metrics

231

Cite this

GOST |

Cite this

GOST Copy

Wilson N. C. et al. An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells // Cancer Cell. 2011. Vol. 19. No. 1. pp. 101-113.

GOST all authors (up to 50) Copy

Wilson N. C., Yang B., Yang A., Loeser S., Marsters S., Lawrence D. M., Li Y., Pitti R., TOTPAL K., Yee S., Ross S., Vernes J., Lu Y., Adams C., Offringa R., Kelley B., Hymowitz S. G., Daniel D., Meng G., Ashkenazi A. An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells // Cancer Cell. 2011. Vol. 19. No. 1. pp. 101-113.

RIS |

Cite this

RIS Copy

TY - JOUR

DO - 10.1016/j.ccr.2010.11.012

UR - https://doi.org/10.1016/j.ccr.2010.11.012

TI - An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells

T2 - Cancer Cell

AU - Wilson, Nicholas C.

AU - Yang, Becky

AU - Yang, Annie

AU - Loeser, Stefanie

AU - Marsters, Scot

AU - Lawrence, David M.

AU - Li, Yun

AU - Pitti, Robert

AU - TOTPAL, KLARA

AU - Yee, Sharon

AU - Ross, Sarajane

AU - Vernes, Jean-Michel

AU - Lu, Yanmei

AU - Adams, Cam

AU - Offringa, Rienk

AU - Kelley, Bob

AU - Hymowitz, Sarah G.

AU - Daniel, Dylan

AU - Meng, Gloria

AU - Ashkenazi, Avi

PY - 2011

DA - 2011/01/20

PB - Elsevier

SP - 101-113

IS - 1

VL - 19

PMID - 21251615

SN - 1535-6108

SN - 1878-3686

ER -

BibTex |

Cite this

BibTex (up to 50 authors) Copy

@article{2011_Wilson,

author = {Nicholas C. Wilson and Becky Yang and Annie Yang and Stefanie Loeser and Scot Marsters and David M. Lawrence and Yun Li and Robert Pitti and KLARA TOTPAL and Sharon Yee and Sarajane Ross and Jean-Michel Vernes and Yanmei Lu and Cam Adams and Rienk Offringa and Bob Kelley and Sarah G. Hymowitz and Dylan Daniel and Gloria Meng and Avi Ashkenazi},

title = {An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells},

journal = {Cancer Cell},

year = {2011},

volume = {19},

publisher = {Elsevier},

month = {jan},

url = {https://doi.org/10.1016/j.ccr.2010.11.012},

number = {1},

pages = {101--113},

doi = {10.1016/j.ccr.2010.11.012}

}

MLA

Cite this

MLA Copy

Wilson, Nicholas C., et al. “An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells.” Cancer Cell, vol. 19, no. 1, Jan. 2011, pp. 101-113. https://doi.org/10.1016/j.ccr.2010.11.012.

Publisher

Elsevier

Journal

Cancer Cell

scimago Q1

wos Q1

SJR

19.027

CiteScore

57.7

Impact factor

44.5

ISSN

15356108 (Print)

18783686 (Electronic)